Group 1 - The company reported an increase in revenue to RMB 10.9 million for the six months ending June 30, 2025, compared to no revenue in the same period of 2024, primarily due to income generated from granting intellectual property licenses [1] - Research and development costs rose by 46.0% to RMB 299.6 million for the same period, up from RMB 205.2 million in the previous year, driven by increased clinical trial expenses and other factors [1] - Clinical trial expenses increased from RMB 71.6 million to RMB 95.9 million, mainly due to the REC610 entering Phase III clinical trials at the end of 2024 [1] Group 2 - The company's vaccine portfolio strategically covers eight major disease areas, including HPV and respiratory syncytial virus, with over 10 candidate vaccines [2] - The company is conducting a Phase III clinical trial for REC603 in China and has completed the 42-month follow-up, with plans to submit a BLA application in 2026 [2] - Future strategies include accelerating the development and commercialization of candidate vaccines, enhancing research capabilities, and pursuing internationalization through "going out" and "bringing in" strategies [2]

Core Viewpoint - 瑞科生物-B (02179) reported a significant increase in revenue for the first half of 2025, primarily due to income generated from granting intellectual property licenses, despite a substantial loss for the period [1] Financial Performance - Revenue from continuing operations reached 10.899 million RMB, compared to none in the same period last year [1] - The loss attributable to equity holders of the parent company was 341 million RMB, representing a year-on-year increase of 36.7% [1] - Basic loss per share was 0.71 RMB [1]

Group 1 - The company reported a revenue of 10.899 million yuan for the first half of 2025, compared to no revenue in the same period last year [1] - The loss attributable to the parent company increased to 341 million yuan, representing a year-on-year increase of 36.7% [1] - The basic loss per share was 0.71 yuan [1] Group 2 - The increase in revenue was primarily due to income generated from granting intellectual property licenses during the period [1]

Financial Performance - For the six months ended June 30, 2025, the company reported revenue of RMB 10,899 thousand, compared to no revenue in the same period of 2024[9] - Other income and gains decreased to RMB 12,102 thousand from RMB 35,701 thousand year-on-year, representing a decline of approximately 66.1%[9] - The company recorded a pre-tax loss of RMB 339,573 thousand, which is an increase of 36% compared to a pre-tax loss of RMB 249,636 thousand in 2024[9] - The net loss for the period was RMB 340,653 thousand, compared to a net loss of RMB 249,636 thousand in the previous year, indicating a year-on-year increase of 36.4%[9] - Basic and diluted loss per share was RMB 0.71, compared to RMB 0.52 in the same period of 2024[9] Assets and Liabilities - The total non-current assets amounted to RMB 1,261,034 thousand, a slight decrease from RMB 1,285,103 thousand as of December 31, 2024[10] - Current assets decreased significantly to RMB 281,657 thousand from RMB 655,129 thousand, indicating a reduction of approximately 57.0%[10] - The total current liabilities increased to RMB 881,452 thousand from RMB 839,420 thousand, reflecting a rise of about 5.0%[10] - The total equity decreased to RMB 177,634 thousand from RMB 529,324 thousand, showing a decline of approximately 66.5%[10] - The net current liabilities reached RMB 599,795,000, compared to RMB 184,291,000 in the previous year, indicating a substantial increase in financial pressure[12] Research and Development - The company is advancing its product pipeline, including the REC603 HPV vaccine, with plans to submit a BLA application in 2026 following interim analysis[3] - Research and development costs increased to RMB 299,582,000 for the six months ended June 30, 2025, compared to RMB 205,222,000 in 2024, reflecting a growth of 45.8%[27] - The company is focused on developing innovative vaccines, with a pipeline that includes over 10 candidates, including the strategic products REC610 and REC603, both in Phase III clinical trials[40] - The company has established a comprehensive vaccine innovation engine, which includes advanced platforms for adjuvant and protein engineering, enabling the development of innovative vaccines[41] - The company has developed advanced technology platforms for adjuvant development, protein engineering, and immunological evaluation, facilitating the discovery of subunit vaccines[70] Clinical Trials and Product Development - REC603, the core product, is currently in the critical phase of the Phase III clinical trial in China, with a total sample size of 16,050 participants[48] - The new adjuvant recombinant quadrivalent HPV vaccine (REC604a) has received clinical trial approval from the National Medical Products Administration[46] - The recombinant zoster vaccine (REC610) has also received clinical trial approval and is set to initiate Phase III trials in October 2024[46] - The bivalent recombinant respiratory syncytial virus vaccine (REC625) is expected to complete preclinical research by 2025[46] - The company plans to submit the Biologics License Application (BLA) for REC603 by 2026, following the completion of the Phase III trial and interim analysis[49] Financial Strategy and Capital Management - The company has received approval from the China Securities Regulatory Commission to issue shares to Yangtze River Pharmaceutical Group for a total consideration of RMB 800,000,000, expected to be completed by September 30, 2025[17] - The company has secured unused credit facilities totaling RMB 130,000,000, available until June 30, 2026, to support its operational needs[17] - The company plans to issue up to 143,112,702 domestic shares at a subscription price of RMB 5.59 per share to enhance its business development and financial structure[115] - Approximately RMB 800 million is expected to be raised from the share issuance, with about 70% allocated to the shingles vaccine project and 30% for working capital[116][118] - The company aims to maintain sufficient cash and cash equivalents to meet its working capital needs and mitigate cash flow volatility[113] Market Position and Future Outlook - The company operates primarily in the vaccine research and development sector within mainland China, with no significant revenue from other regions reported[14] - The company is focusing on expanding its vaccine portfolio to address various viral infections, including HPV and respiratory viruses, to meet market demand[46] - The company reported a significant increase in revenue, with a year-over-year growth of 25% in Q2 2023[136] - The company projects a revenue guidance of $500 million for Q3 2023, reflecting a 20% growth from Q2 2023[136] - Future outlook remains positive, with anticipated growth driven by new product launches and market expansion strategies[136]

Core Viewpoint - 瑞科生物-B (02179.HK) will hold a board meeting on August 29, 2025, to review and approve the unaudited interim results for the six months ending June 30, 2025, and to consider the distribution of an interim dividend, if any [1] Group 1 - The board meeting is scheduled for August 29, 2025 [1] - The meeting will focus on the unaudited interim results for the six months ending June 30, 2025 [1] - The company will also consider the potential distribution of an interim dividend [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Jiangsu Recbio Technology Co., Ltd. 江蘇瑞科生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2179） 董事會會議召開日期 江蘇瑞科生物技術股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈，董事 會會議將於2025年8月29日（星期五）舉行，藉以（其中包括）審議及批准本公司及 其附屬公司截至2025年6月30日止六個月之未經審核中期業績及其發佈，並考慮 派發中期股息（如有）。 承董事會命 江蘇瑞科生物技術股份有限公司 主席 劉勇博士 中國江蘇省，2025年8月19日 於本公告日期，董事會包括董事會主席兼執行董事劉勇博士，執行董事李布先 生、陳青青女士及洪坤學博士，非執行董事王如偉博士、張佳鑫博士、周宏斌博 士及胡厚偉先生，以及獨立非執行董事夏立軍博士、梁國棟先生、GAO Feng教授 及袁銘輝教授。 ...

江蘇瑞科生物技術股份有限公司 章程 第三條 公司的發起人為以下四十八方：泰州元工科技合夥企業（有限 合夥）、上海超瑞醫藥科技合夥企業（有限合夥）、北京君聯晟 源股權投資合夥企業（有限合夥）、南京招銀現代產業貳號股權 投資基金（有限合夥）、LYFE Niagara River Limited、深圳市富 海新材二期創業投資基金合夥企業（有限合夥）、深圳盈科進投 資管理合夥企業（有限合夥）、深圳市紅杉瀚辰股權投資合夥企 業（有限合夥）、珠海君聯永碩股權投資企業（有限合夥）、SCC Growth VI Holdco C (HK) Limited、深圳富海雋永二號創業投 資企業（有限合夥）、連雲港瑞百泰醫藥科技合夥企業（有限合 夥）、江蘇疌泉中衛騰雲醫藥健康產業投資基金（有限合夥）、 上海濟玥企業管理合夥企業（有限合夥）、上海濟軒企業管理諮 詢合夥企業（有限合夥）、寧波梅山保稅港區浩金致同股權投資 合夥企業（有限合夥）、祥峰（廈門）投資合夥企業（有限合夥）、 泰州中國醫藥城一類新藥研發投資基金合夥企業（有限合夥）、 贛州浩金致遠股權投資中心（有限合夥）、瀏陽沃陽健康產業投 1 二〇二五年八月 | 目錄 | | --- ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 2 Jiangsu Recbio Technology Co., Ltd. 江蘇瑞科生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2179） 關於變更經營範圍及修訂公司章程 完成工商登記及換領營業執照的公告 茲提述江蘇瑞科生物技術股份有限公司（「本公司」）日期分別為2025年5月21日及 2025年6月20日的公告以及日期均為2025年5月30日的年度股東大會通告及通函 （「該通函」），內容有關（其中包括）建議變更經營範圍及建議修訂公司章程及相關 事宜的詳情。除文義另有所指外，本公告所用詞彙與該通函所界定者具有相同涵 義。 本公司於2025年6月20日召開年度股東大會，審議通過了該通函提述的(1)關於 建議變更本公司經營範圍的議案；及(2)關於建議修訂公司章程的議案（「該等議 案」）。建議變更經營範圍將自市場監督管理部門頒發新營業執照當日起生效， 而修訂後的公司章程將自建 ...

第 1 頁 共 11 頁 v 1.1.1 | 3. 股份分類 | 普通股 | 股份類別 | H | 於香港聯交所上市 (註1) | 是 | | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02179 | 說明 | | | | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 非上市外資股 | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 12,000,000 RMB | | 1 RMB | | 12,000,000 | | 增加 / 減少 (-) | | | 0 | | RMB | | 0 | | 本月底結存 | | | 12,000,000 RMB | | 1 RMB | | 12,000,000 | | 1. 股份分類 | 普通股 | 股份類別 | | ...

Core Viewpoint - The company has signed a product licensing cooperation agreement with Indian BE Company for the restructuring of the nine-valent HPV vaccine REC603, granting exclusive rights for development, production, and commercialization in India and in tender markets led by UNICEF and PAHO [1] Group 1 - The company has received an upfront payment for the collaboration [1] - The company will receive milestone payments based on the progress of the collaboration [1] - The company will also earn royalties based on annual net sales [1]